<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2016-9-2-96-101</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-34</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FOR OPHTHALMOLOGY PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Международные мультицентровые исследования по глаукоме</article-title><trans-title-group xml:lang="en"><trans-title>International Multicenter Glaucoma Research</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>S. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ловпаче</surname><given-names>Дж. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Lovpache</surname><given-names>D. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брежнев</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Brezhnev</surname><given-names>A. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «НИИ глазных болезней», Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Eye Diseases, Moscow, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Московский НИИ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz Research Institute of Eye Diseases, Moscow, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБОУ ВПО КГМУ Минздрава России, Курск</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kursk State Medical University, Kursk, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>03</day><month>10</month><year>2018</year></pub-date><volume>9</volume><issue>2</issue><fpage>96</fpage><lpage>101</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Петров С.Ю., Ловпаче Д.Н., Брежнев А.Ю., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Петров С.Ю., Ловпаче Д.Н., Брежнев А.Ю.</copyright-holder><copyright-holder xml:lang="en">Petrov S.Y., Lovpache D.N., Brezhnev A.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/34">https://roj.igb.ru/jour/article/view/34</self-uri><abstract><p>В обзоре представлены результаты крупномасштабных международных мультицентровых исследований по глаукоме, оказавших существенное влияние на сегодняшнее понимание стратегий диагностики и лечения данной патологии. Выводы этих исследований многократно цитируются в офтальмологической литературе, однако их структура, необходимая для понимания и корректной интерпретации деталей и результатов этих исследований, нередко остается за кадром. Рандомизированные клинические исследования имеют крайне важное практическое значение для выбора правильной тактики ведения пациентов с глаукомой и офтальмогипертензией. Впервые в этих исследованиях продемонстрировано, что снижение внутриглазного давления (ВГД) явным образом замедляет прогрессирование глаукомы и уменьшает вероятность перехода офтальмогипертензии в глаукому. Снижение ВГД замедляет прогрессирование глаукомы даже при его условно нормальном уровне, причем риск прогрессирования сокращается весьма значительно (по некоторым данным, примерно на 10 % на каждый мм рт. ст. уменьшения ВГД). Отмечена более выраженная степень и длительность компенсации ВГД при различной хирургической тактике (аргон-лазерная трабекулопластика, трабекулэктомия), однако и риск осложнений при этом различен. Выявлены основные факторы риска прогрессирования глаукомы (пожилой возраст, повышенное ВГД, геморрагии диска зрительного нерва) и перехода офтальмогипертензии в глаукому (повышенное ВГД, пожилой возраст, меньшая центральная толщина роговицы и геморрагии диска зрительного нерва). Выявлено, что скорость прогрессирования определяется также уровнем офтальмотонуса на момент выявления заболевания и стадией болезни. Кроме того, ставится вопрос дифференцированного индивидуального подхода к выбору тактики ведения пациентов, в том числе и возможность применения выжидательной тактики в условиях адекватного мониторинга ключевых параметров прогресса, особенно периметрических индексов и состояния зрительного нерва. Результаты данных рандомизированных клинических исследований позволяют не только сделать терапию более целенаправленной и эффективной, но и сформулировать доказательную базу ведения пациентов в различных клинических ситуациях // Российский офтальмологический журнал, 2016; 2: 96-101 . </p></abstract><trans-abstract xml:lang="en"><p>The review paper presents the results of large-scale international multicenter research of glaucoma. The research has a considerable impact on today’s understanding of strategies of glaucoma diagnosis and treatment. The conclusions made by the authors of this research are heavily cited in ophthalmological literature but its structure, vital for proper interpretation of research details and results, is often disregarded. Randomized clinical studies are extremely important for the selection of correct management of patients with glaucoma or ocular hypertension. The reviewed research showed, for the first time, that IOP reduction definitely slows the progression of glaucoma and reduces the probability that ocular hypertension develops into glaucoma. IOP reduction slows down the progression of glaucoma even if its level is conditionally normal, and the risk of progression is reduced drastically (by some estimates, this risk drops about 10 % per 1 mmHg of IOP reduction). It is noted that various surgical interventions (argon laser trabeculoplasty, trabeculectomy) increase the degree and duration of IOP compensation, but the risk of complications may be different for different operations. The research identifies the major risk factors of glaucoma progression (advanced age, increased IOP, optic disc hemorrhages) and of transition of ocular hypertension to glaucoma (increased IOP, age, lower central corneal thickness and optic disc hemorrhages). The progression rate has been found to depend on the intraocular pressure level as measured at the moment of the detection of the disease, and on the stage of the disease. Besides, the study suggests a differentiated approach to the choice of patient management tactics, including the choice of “wait-and-see” tactics under adequate monitoring of the key parameters of progression, especially of perimeter indices and the condition of the optic nerve. The results of randomized clinical studies permit to achieve a more targeted and effective glaucomatous therapy and to form an evidence-based management of patients in different clinical situations // Russian Ophthalmological Journal, 2016; 2: 96-101 . doi: 10.21516/2072-0076-2016-9-2-96-101 . </p></trans-abstract><kwd-group xml:lang="ru"><kwd>глаукома</kwd><kwd>офтальмогипертензия</kwd><kwd>внутриглазное давление</kwd><kwd>факторы риска</kwd><kwd>параметры прогрессирования</kwd><kwd>glaucoma</kwd><kwd>ocular hypertension</kwd><kwd>intraocular pressure</kwd><kwd>risk factors</kwd><kwd>progression markers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. American Journal of Ophthalmology. 1998; 126 (4): 487-97.</mixed-citation><mixed-citation xml:lang="en">Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. American Journal of Ophthalmology. 1998; 126 (4): 487-97.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. American Journal of Ophthalmology. 1998; 126 (4): 498-505.</mixed-citation><mixed-citation xml:lang="en">The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. American Journal of Ophthalmology. 1998; 126 (4): 498-505.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson D.R., Drance S.M., Schulzer M. Collaborative Normal-Tension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. American Journal of Ophthalmology. 2003; 136 (5): 820-9.</mixed-citation><mixed-citation xml:lang="en">Anderson D.R., Drance S.M., Schulzer M. Collaborative Normal-Tension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. American Journal of Ophthalmology. 2003; 136 (5): 820-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson D.R., Drance S.M., Schulzer M. Collaborative Normal-Tension Glaucoma StudyGroup. Natural history of normal-tension glaucoma. Ophthalmology. 2001; 108 (2): 247-53.</mixed-citation><mixed-citation xml:lang="en">Anderson D.R., Drance S.M., Schulzer M. Collaborative Normal-Tension Glaucoma StudyGroup. Natural history of normal-tension glaucoma. Ophthalmology. 2001; 108 (2): 247-53.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Drance S., Anderson D.R., Schulzer M. Collaborative Normal-Tension Glaucoma StudyGroup. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. American Journal of Ophthalmology 2001; 131 (6): 699-708.</mixed-citation><mixed-citation xml:lang="en">Drance S., Anderson D.R., Schulzer M. Collaborative Normal-Tension Glaucoma StudyGroup. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. American Journal of Ophthalmology 2001; 131 (6): 699-708.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Leske M.C., Heijl A., Hyman L., Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999; 106 (11): 2144-53.</mixed-citation><mixed-citation xml:lang="en">Leske M.C., Heijl A., Hyman L., Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999; 106 (11): 2144-53.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bengtsson B., Leske M.C., Hyman L., Heijl A. Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114 (2): 205-9.</mixed-citation><mixed-citation xml:lang="en">Bengtsson B., Leske M.C., Hyman L., Heijl A. Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114 (2): 205-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Leske M.C., Bengtsson B., Bengtsson B., Hussein M. Early Manifest GlaucomaTrialGroup. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmologica Scandinavica. 2003; 81 (3): 286-93.</mixed-citation><mixed-citation xml:lang="en">Heijl A., Leske M.C., Bengtsson B., Bengtsson B., Hussein M. Early Manifest GlaucomaTrialGroup. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmologica Scandinavica. 2003; 81 (3): 286-93.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002; 120 (10): 1268-79.</mixed-citation><mixed-citation xml:lang="en">Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002; 120 (10): 1268-79.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hyman L.G., Komaroff E., Heijl A., Bengtsson B., Leske M.C. Early Manifest GlaucomaTrial Group. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005; 112(9): 1505-13.</mixed-citation><mixed-citation xml:lang="en">Hyman L.G., Komaroff E., Heijl A., Bengtsson B., Leske M.C. Early Manifest GlaucomaTrial Group. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005; 112(9): 1505-13.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Archives of Ophthalmology. 2003; 121(1): 48-56.</mixed-citation><mixed-citation xml:lang="en">Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Archives of Ophthalmology. 2003; 121(1): 48-56.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Leske M.C., Heijl A., Hyman L., et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(11): 1965-72.</mixed-citation><mixed-citation xml:lang="en">Leske M.C., Heijl A., Hyman L., et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(11): 1965-72.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Leske M.C., Hyman L., et al. Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. Acta Ophthalmologica. 2011; 89 (8): 749-54.</mixed-citation><mixed-citation xml:lang="en">Heijl A., Leske M.C., Hyman L., et al. Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. Acta Ophthalmologica. 2011; 89 (8): 749-54.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Peters D., Leske M.C., Bengtsson B. Effects of argon laser trabeculoplasty in the Early Manifest Glaucoma Trial. American Journal of Ophthalmology. 2011; 152 (5): 842-8.</mixed-citation><mixed-citation xml:lang="en">Heijl A., Peters D., Leske M.C., Bengtsson B. Effects of argon laser trabeculoplasty in the Early Manifest Glaucoma Trial. American Journal of Ophthalmology. 2011; 152 (5): 842-8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hyman L., Heijl A., Leske M.C., Bengtsson B., Yang Z. Early Manifest Glaucoma Trial Group. Natural history of intraocular pressure in the early manifest glaucoma trial: A 6-year follow-up. Archives of Ophthalmology. 2010; 128(5): 601-7.</mixed-citation><mixed-citation xml:lang="en">Hyman L., Heijl A., Leske M.C., Bengtsson B., Yang Z. Early Manifest Glaucoma Trial Group. Natural history of intraocular pressure in the early manifest glaucoma trial: A 6-year follow-up. Archives of Ophthalmology. 2010; 128(5): 601-7.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Bengtsson B., Hyman L., Leske M.C. Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology. 2009; 116 (12): 2271-6.</mixed-citation><mixed-citation xml:lang="en">Heijl A., Bengtsson B., Hyman L., Leske M.C. Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology. 2009; 116 (12): 2271-6.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Heijl A., Bengtsson B., Chauhan B.C., et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115 (9): 1557-65.</mixed-citation><mixed-citation xml:lang="en">Heijl A., Bengtsson B., Chauhan B.C., et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115 (9): 1557-65.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bengtsson B., Leske M.C., Yang Z., Heijl A., Group E. Disc hemorrhages and treatment in the early manifest glaucoma trial. Ophthalmology. 2008; 115(11): 2044-8.</mixed-citation><mixed-citation xml:lang="en">Bengtsson B., Leske M.C., Yang Z., Heijl A., Group E. Disc hemorrhages and treatment in the early manifest glaucoma trial. Ophthalmology. 2008; 115(11): 2044-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gordon M.O., Kass M.A. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Archives of Ophthalmology. 1999; 117 (5): 573-83.</mixed-citation><mixed-citation xml:lang="en">Gordon M.O., Kass M.A. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Archives of Ophthalmology. 1999; 117 (5): 573-83.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; 120(6): 701-13; discussion: 829-30.</mixed-citation><mixed-citation xml:lang="en">Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; 120(6): 701-13; discussion: 829-30.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kass M.A., Gordon M.O., Gao F., et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Archives of Ophthalmology. 2010; 128 (3): 276-87.</mixed-citation><mixed-citation xml:lang="en">Kass M.A., Gordon M.O., Gao F., et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Archives of Ophthalmology. 2010; 128 (3): 276-87.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Budenz D.L., Anderson D.R., Feuer W.J., et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology. 2006; 113 (12): 2137-43.</mixed-citation><mixed-citation xml:lang="en">Budenz D.L., Anderson D.R., Feuer W.J., et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology. 2006; 113 (12): 2137-43.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Herman D.C., Gordon M.O., Beiser J.A., et al. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. American Journal of Ophthalmology. 2006; 142 (5): 800-10.</mixed-citation><mixed-citation xml:lang="en">Herman D.C., Gordon M.O., Beiser J.A., et al. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. American Journal of Ophthalmology. 2006; 142 (5): 800-10.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bhorade A.M., Wilson B.S., Gordon M.O., et al. The utility of the monocular trial: data from the ocular hypertension treatment study. Ophthalmology. 2010; 117 (11): 2047-54.</mixed-citation><mixed-citation xml:lang="en">Bhorade A.M., Wilson B.S., Gordon M.O., et al. The utility of the monocular trial: data from the ocular hypertension treatment study. Ophthalmology. 2010; 117 (11): 2047-54.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Barnett E.M., Fantin A., Wilson B.S., Kass M.A., Gordon M.O. Ocular Hypertension Treatment Study Group. The incidence of retinal vein occlusion in the ocular hypertension treatment study. Ophthalmology. 2010; 117 (3): 484-8.</mixed-citation><mixed-citation xml:lang="en">Barnett E.M., Fantin A., Wilson B.S., Kass M.A., Gordon M.O. Ocular Hypertension Treatment Study Group. The incidence of retinal vein occlusion in the ocular hypertension treatment study. Ophthalmology. 2010; 117 (3): 484-8.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Miglior S., Zeyen T., Pfeiffer N., et al. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology. 2002; 109 (9): 1612-21.</mixed-citation><mixed-citation xml:lang="en">Miglior S., Zeyen T., Pfeiffer N., et al. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology. 2002; 109 (9): 1612-21.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Miglior S., Zeyen T., Pfeiffer N., et al. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005; 112 (3): 366-75.</mixed-citation><mixed-citation xml:lang="en">Miglior S., Zeyen T., Pfeiffer N., et al. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005; 112 (3): 366-75.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Miglior S., Pfeiffer N., Torri V., et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. 2007; 114 (1): 3-9.</mixed-citation><mixed-citation xml:lang="en">Miglior S., Pfeiffer N., Torri V., et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. 2007; 114 (1): 3-9.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Musch D.C., Lichter P.R., Guire K.E., Standardi C.L. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106(4): 653-62.</mixed-citation><mixed-citation xml:lang="en">Musch D.C., Lichter P.R., Guire K.E., Standardi C.L. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106(4): 653-62.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lichter P.R., Musch D.C., Gillespie B.W., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108 (11): 1943-53.</mixed-citation><mixed-citation xml:lang="en">Lichter P.R., Musch D.C., Gillespie B.W., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108 (11): 1943-53.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Musch D.C., Gillespie B.W., Niziol L.M., Cashwell L.F., Lichter P.R. Collaborative Initial Glaucoma Treatment StudyGroup. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2008; 115 (6): 927-33.</mixed-citation><mixed-citation xml:lang="en">Musch D.C., Gillespie B.W., Niziol L.M., Cashwell L.F., Lichter P.R. Collaborative Initial Glaucoma Treatment StudyGroup. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2008; 115 (6): 927-33.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Musch D.C., Gillespie B.W., Niziol L.M., et al. Cataract extraction in the collaborative initial glaucoma treatment study: incidence, risk factors, and the effect of cataract progression and extraction on clinical and quality-of-life outcomes. Archives of ophthalmology. 2006; 124 (12): 1694-700.</mixed-citation><mixed-citation xml:lang="en">Musch D.C., Gillespie B.W., Niziol L.M., et al. Cataract extraction in the collaborative initial glaucoma treatment study: incidence, risk factors, and the effect of cataract progression and extraction on clinical and quality-of-life outcomes. Archives of ophthalmology. 2006; 124 (12): 1694-700.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Musch D.C., Gillespie B.W., Lichter P.R., et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2009; 116 (2): 200-7.</mixed-citation><mixed-citation xml:lang="en">Musch D.C., Gillespie B.W., Lichter P.R., et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2009; 116 (2): 200-7.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Musch D.C., Gillespie B.W., Niziol L.M., et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011; 118 (9): 1766-73.</mixed-citation><mixed-citation xml:lang="en">Musch D.C., Gillespie B.W., Niziol L.M., et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011; 118 (9): 1766-73.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Janz N.K., Wren P.A., Lichter P.R., et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001; 108 (11): 1954-65.</mixed-citation><mixed-citation xml:lang="en">Janz N.K., Wren P.A., Lichter P.R., et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001; 108 (11): 1954-65.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Parrish R.K., 2nd, Feuer W.J., Schiffman J.C., et al. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. American Journal of Ophthalmology. 2009; 147 (4): 717-24 e1.</mixed-citation><mixed-citation xml:lang="en">Parrish R.K., 2nd, Feuer W.J., Schiffman J.C., et al. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. American Journal of Ophthalmology. 2009; 147 (4): 717-24 e1.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ederer F., Gaasterland D.E., Sullivan E.K., Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Controlled clinical trials. 1994; 15 (4): 299-325.</mixed-citation><mixed-citation xml:lang="en">Ederer F., Gaasterland D.E., Sullivan E.K., Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Controlled clinical trials. 1994; 15 (4): 299-325.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. American Journal of Ophthalmology. 2000; 130 (4): 429-40.</mixed-citation><mixed-citation xml:lang="en">The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. American Journal of Ophthalmology. 2000; 130 (4): 429-40.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. The AGIS Investigators. Archives of Ophthalmology. 2000; 118 (12): 1639-52.</mixed-citation><mixed-citation xml:lang="en">The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. The AGIS Investigators. Archives of Ophthalmology. 2000; 118 (12): 1639-52.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ederer F., Gaasterland D.A., Dally L.G., et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology. 2004; 111 (4): 651-64.</mixed-citation><mixed-citation xml:lang="en">Ederer F., Gaasterland D.A., Dally L.G., et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology. 2004; 111 (4): 651-64.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">AGIS Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology. 2001; 132(3): 311-20.</mixed-citation><mixed-citation xml:lang="en">AGIS Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. American Journal of Ophthalmology. 2001; 132(3): 311-20.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Nouri-Mahdavi K., Hoffman D., Coleman A.L., et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004; 111 (9): 1627-35.</mixed-citation><mixed-citation xml:lang="en">Nouri-Mahdavi K., Hoffman D., Coleman A.L., et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004; 111 (9): 1627-35.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Caprioli J., Coleman A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008; 115 (7): 1123-9 e3.</mixed-citation><mixed-citation xml:lang="en">Caprioli J., Coleman A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008; 115 (7): 1123-9 e3.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">AGIS Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology. 2002; 134 (4): 481-98.</mixed-citation><mixed-citation xml:lang="en">AGIS Investigators A. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. American Journal of Ophthalmology. 2002; 134 (4): 481-98.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
